AR040719A1 - Proceso para la produccion de una proteina heterologa - Google Patents

Proceso para la produccion de una proteina heterologa

Info

Publication number
AR040719A1
AR040719A1 AR20030102713A ARP030102713A AR040719A1 AR 040719 A1 AR040719 A1 AR 040719A1 AR 20030102713 A AR20030102713 A AR 20030102713A AR P030102713 A ARP030102713 A AR P030102713A AR 040719 A1 AR040719 A1 AR 040719A1
Authority
AR
Argentina
Prior art keywords
production
heterologous protein
inclusion bodies
conditions
heterological
Prior art date
Application number
AR20030102713A
Other languages
English (en)
Spanish (es)
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of AR040719A1 publication Critical patent/AR040719A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AR20030102713A 2002-07-31 2003-07-29 Proceso para la produccion de una proteina heterologa AR040719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200200187A SI21273A (sl) 2002-07-31 2002-07-31 Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina

Publications (1)

Publication Number Publication Date
AR040719A1 true AR040719A1 (es) 2005-04-20

Family

ID=31713326

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102713A AR040719A1 (es) 2002-07-31 2003-07-29 Proceso para la produccion de una proteina heterologa

Country Status (9)

Country Link
US (1) US20050283000A1 (https=)
EP (1) EP1527188B1 (https=)
JP (2) JP4703186B2 (https=)
AR (1) AR040719A1 (https=)
AT (1) ATE456665T1 (https=)
AU (1) AU2003250347A1 (https=)
DE (1) DE60331149D1 (https=)
SI (2) SI21273A (https=)
WO (1) WO2004015124A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21639A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
EP1939212A1 (en) * 2006-12-20 2008-07-02 LEK Pharmaceuticals D.D. Organic compounds
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
JPWO2008133141A1 (ja) * 2007-04-24 2010-07-22 東洋紡績株式会社 オスモチン組換えタンパク質およびその製造方法、並びにその利用
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
US20090294362A1 (en) * 2008-05-30 2009-12-03 Persson Jonas Par Stationary phase for hydrophilic interaction chromatography
EP2542574B1 (en) * 2010-03-04 2017-08-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
AU2011235210B2 (en) 2010-04-01 2015-07-16 Pfenex Inc. Methods for G-CSF production in a Pseudomonas host cell
JP5836621B2 (ja) 2011-03-31 2015-12-24 株式会社マキタ 動力工具
HUP1200171A1 (hu) * 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
WO2014126871A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
RU2016117275A (ru) * 2013-11-01 2017-12-04 Сфериум Биомед С.Л. Тельца включения для трансдермальной доставки терапевтических и косметических средств
CN104152515B (zh) * 2014-08-14 2019-12-31 江苏奥赛康药业有限公司 一种制备重组人粒细胞集落刺激因子的培养基及发酵方法
JP2020080727A (ja) * 2018-11-26 2020-06-04 Spiber株式会社 目的タンパク質の製造方法
KR20230044394A (ko) * 2020-06-09 2023-04-04 아이코사백스, 인크. 바이러스 유사 입자를 제조하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
DE4037196A1 (de) * 1990-11-22 1992-05-27 Boehringer Mannheim Gmbh Verfahren zur reaktivierung von denaturiertem protein
AU6028396A (en) * 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
WO1998029542A1 (en) * 1996-12-27 1998-07-09 Japan Tobacco Inc. Floral organ-specific genes and promoter sequences thereof
US20020052026A1 (en) * 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
US6677139B1 (en) * 1999-12-23 2004-01-13 Genecor International, Inc. Methods for production of proteins in host cells
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
SI21102A (sl) * 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika

Also Published As

Publication number Publication date
EP1527188B1 (en) 2010-01-27
SI1527188T1 (sl) 2010-05-31
WO2004015124A1 (en) 2004-02-19
EP1527188A1 (en) 2005-05-04
JP4703186B2 (ja) 2011-06-15
US20050283000A1 (en) 2005-12-22
JP2006502708A (ja) 2006-01-26
AU2003250347A1 (en) 2004-02-25
JP2011078421A (ja) 2011-04-21
DE60331149D1 (de) 2010-03-18
SI21273A (sl) 2004-02-29
ATE456665T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
AR040719A1 (es) Proceso para la produccion de una proteina heterologa
BRPI0611350B8 (pt) formulação, seus usos e seu processo de fabricação,e artigo de fabricação
ECSP078005A (es) Proceso de fabricación para tigeciclina
CL2008001897A1 (es) Proceso para la preparacion de 3-halometil-1-metil-1h-pirazol, utiles como intermediario en la produccion de fungicidas; compuestos derivados de 3-halometil-1-metil-1h-pirazol.
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
ECSP055864A (es) Derivados sustituidos del pirrolo-pirazol como inhibidores de la quinasa
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
DOP2012000170A (es) Proceso para la fabricacion de un agente farmaceuticamante activo
UY29183A1 (es) Formulaciones
SV2006002288A (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) ref. p-sv-79054/ug
AR088079A1 (es) Metodos para la produccion en sitio de un desinfectante estable para su uso como composicion biocida
GT200800117A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y uso
MX2019011730A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
EA201992516A1 (ru) Способ получения бифункциональных белков и их производных
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
MA28635B1 (fr) Methode de production de derives de 1, 4-diphenylazetidinone
AR054735A1 (es) Proceso de obtencion de un derivado de piperazina
ECSP045145A (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
ECSP024377A (es) Derivados de benzo (g) quinolina
MA28576B1 (fr) Procede de preparation de derives n-piperidino-1,5-diphenylpyrazole-3-carboxamide.

Legal Events

Date Code Title Description
FB Suspension of granting procedure